Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Glomerular diseases in pregnancy: pragmatic recommendations for clinical management.
Fakhouri F, Schwotzer N, Cabiddu G, Barratt J, Legardeur H, Garovic V, Orozco-Guillen A, Wetzels J, Daugas E, Moroni G, Noris M, Audard V, Praga M, Llurba E, Wuerzner G, Attini R, Desseauve D, Zakharova E, Luders C, Wiles K, Leone F, Jesudason S, Costedoat-Chalumeau N, Kattah A, Soto-Abraham V, Karras A, Prakash J, Lightstone L, Ronco P, Ponticelli C, Appel G, Remuzzi G, Tsatsaris V, Piccoli GB. Fakhouri F, et al. Among authors: barratt j. Kidney Int. 2023 Feb;103(2):264-281. doi: 10.1016/j.kint.2022.10.029. Epub 2022 Dec 5. Kidney Int. 2023. PMID: 36481180 Review.
Treatment of IgA nephropathy.
Barratt J, Feehally J. Barratt J, et al. Kidney Int. 2006 Jun;69(11):1934-8. doi: 10.1038/sj.ki.5000419. Kidney Int. 2006. PMID: 16641928 Free article. Review.
Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments.
Coppo R, Troyanov S, Bellur S, Cattran D, Cook HT, Feehally J, Roberts IS, Morando L, Camilla R, Tesar V, Lunberg S, Gesualdo L, Emma F, Rollino C, Amore A, Praga M, Feriozzi S, Segoloni G, Pani A, Cancarini G, Durlik M, Moggia E, Mazzucco G, Giannakakis C, Honsova E, Sundelin BB, Di Palma AM, Ferrario F, Gutierrez E, Asunis AM, Barratt J, Tardanico R, Perkowska-Ptasinska A; VALIGA study of the ERA-EDTA Immunonephrology Working Group. Coppo R, et al. Among authors: barratt j. Kidney Int. 2014 Oct;86(4):828-36. doi: 10.1038/ki.2014.63. Epub 2014 Apr 2. Kidney Int. 2014. PMID: 24694989 Free PMC article.
The MEST score provides earlier risk prediction in lgA nephropathy.
Barbour SJ, Espino-Hernandez G, Reich HN, Coppo R, Roberts IS, Feehally J, Herzenberg AM, Cattran DC; Oxford Derivation, North American Validation and VALIGA Consortia; Oxford Derivation North American Validation and VALIGA Consortia. Barbour SJ, et al. Kidney Int. 2016 Jan;89(1):167-75. doi: 10.1038/ki.2015.322. Kidney Int. 2016. PMID: 26759049 Free article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Among authors: barratt j. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Improving treatment decisions using personalized risk assessment from the International IgA Nephropathy Prediction Tool.
Barbour SJ, Canney M, Coppo R, Zhang H, Liu ZH, Suzuki Y, Matsuzaki K, Katafuchi R, Induruwage D, Er L, Reich HN, Feehally J, Barratt J, Cattran DC; International IgA Nephropathy Network. Barbour SJ, et al. Among authors: barratt j. Kidney Int. 2020 Oct;98(4):1009-1019. doi: 10.1016/j.kint.2020.04.042. Epub 2020 May 25. Kidney Int. 2020. PMID: 32464215
Development and testing of an artificial intelligence tool for predicting end-stage kidney disease in patients with immunoglobulin A nephropathy.
Schena FP, Anelli VW, Trotta J, Di Noia T, Manno C, Tripepi G, D'Arrigo G, Chesnaye NC, Russo ML, Stangou M, Papagianni A, Zoccali C, Tesar V, Coppo R; members of the VALIGA study. Schena FP, et al. Kidney Int. 2021 May;99(5):1179-1188. doi: 10.1016/j.kint.2020.07.046. Epub 2020 Sep 2. Kidney Int. 2021. PMID: 32889014
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function.
Heerspink HJL, Cherney D, Postmus D, Stefánsson BV, Chertow GM, Dwyer JP, Greene T, Kosiborod M, Langkilde AM, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Toto RD, Wheeler DC; DAPA-CKD Trial Committees and Investigators. Heerspink HJL, et al. Kidney Int. 2022 Jan;101(1):174-184. doi: 10.1016/j.kint.2021.09.005. Epub 2021 Sep 22. Kidney Int. 2022. PMID: 34560136 Free article. Clinical Trial.
446 results